Overview
On 26 March 2014, orphan designation (EU/3/14/1253) was granted by the European Commission to iCell Science AB, Sweden, for ex vivo cultured human mesenchymal stromal cells for the prevention of graft rejection following solid organ transplantation.
Key facts
Active substance |
Ex-vivo cultured human mesenchymal stromal cells
|
Intended use |
Prevention of graft rejection following solid organ transplantation
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1253
|
Date of designation |
26/03/2014
|
Sponsor |
iCell Science AB
Tallmov 2 A 756 45 Uppsala Sweden Tel. +46 183 022 98 E-mail: olle.korsgren@iCell-Science.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: